Company DescriptionBioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.

How the Company Makes Money

BioVaxys Technology Financial Statement Overview

Summary

BioVaxys Technology demonstrates significant financial challenges, with no revenue generation and sustained losses affecting all financial verticals. The balance sheet reveals negative equity, and cash flows are heavily reliant on financing activities. These factors indicate high financial risk and potential sustainability issues in the biotechnology industry.

Income Statement

Very Negative

The company has consistently reported no revenue, resulting in negative EBIT and net income. The lack of revenue growth and profitability highlights significant challenges in the business model or market conditions.

Balance Sheet

Very Negative

The company's balance sheet shows negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is negative, signaling financial instability and potential solvency risks.

Cash Flow

Very Negative

The company exhibits negative operating and free cash flows, reflecting an inability to generate positive cash from operations. Financing cash flow is positive, suggesting reliance on external funding to support operations.

TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	0.00
	EBIT
-2.68M	-3.30M	-2.40M	-4.08M	-6.44M	-1.10M
	EBITDA
-3.63M	-3.95M	-7.69M	0.00	-6.42M	-1.09M
	Net Income Common Stockholders
-5.54M	-3.95M	-7.69M	-11.73M	-6.46M	-1.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
228.98K	211.81K	977.00	141.90K	593.12K	2.42M
	Total Assets
306.26K	1.30M	113.48K	865.56K	8.50M	10.46M
	Total Debt
0.00	68.08K	0.00	0.00	0.00	0.00
	Net Debt
-228.98K	-143.73K	-977.00	-141.90K	-593.12K	-2.42M
	Total Liabilities
116.15K	3.22M	3.49M	1.64M	326.86K	900.09K
	Stockholders Equity
190.11K	-1.92M	-3.37M	-773.53K	8.18M	9.56M
Cash Flow		Free Cash Flow
-2.76M	-2.92M	-1.05M	-1.57M	-5.29M	-1.23M
	Operating Cash Flow
-2.76M	-1.86M	-1.05M	-1.57M	-5.29M	-1.23M
	Investing Cash Flow
-1.06M	-1.06M	0.00	0.00	0.00	61.36K
	Financing Cash Flow
3.01M	3.13M	917.10K	1.11M	3.44M	3.35M

BioVaxys Technology Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVAXF		$8.51M	―		―	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
IOT		C$13.18M	33.97	22.65%	―	―	―
COOL		C$6.83M	―		―	―	―
TBP		$8.47M	―		―	―	―
BETRF		$9.03M	―		―	―	―
GLOW	41 Neutral	C$9.35M	―	-247.04%	―	2733.38%	34.80%

* Healthcare Sector Average

Performance Comparison

BVAXF

BioVaxys Technology

0.03

-0.02

-40.00%

TSE:IOT

Innovotech

0.26

0.18

225.00%

TSE:COOL

Core One Labs

0.14

-0.03

-17.65%

TSE:TBP

Tetra Bio-Pharma

0.02

0.00

0.00%

BETRF

BetterLife Pharma

0.06

-0.03

-33.33%

TSE:GLOW

Glow LifeTech

0.06

0.03

100.00%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.